ATE427750T1 - Verwendung von xenon zur kontrolle von neurologischen defiziten im zusammenhang mit kardiopulmonalem bypass - Google Patents

Verwendung von xenon zur kontrolle von neurologischen defiziten im zusammenhang mit kardiopulmonalem bypass

Info

Publication number
ATE427750T1
ATE427750T1 AT03725356T AT03725356T ATE427750T1 AT E427750 T1 ATE427750 T1 AT E427750T1 AT 03725356 T AT03725356 T AT 03725356T AT 03725356 T AT03725356 T AT 03725356T AT E427750 T1 ATE427750 T1 AT E427750T1
Authority
AT
Austria
Prior art keywords
xenon
cardiopulmonary bypass
neurological deficit
deficit associated
control neurological
Prior art date
Application number
AT03725356T
Other languages
English (en)
Inventor
N P Franks
M Maze
Original Assignee
Protexeon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9935900&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE427750(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Protexeon Ltd filed Critical Protexeon Ltd
Application granted granted Critical
Publication of ATE427750T1 publication Critical patent/ATE427750T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Lubricants (AREA)
  • Credit Cards Or The Like (AREA)
AT03725356T 2002-05-01 2003-05-01 Verwendung von xenon zur kontrolle von neurologischen defiziten im zusammenhang mit kardiopulmonalem bypass ATE427750T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0209998.4A GB0209998D0 (en) 2002-05-01 2002-05-01 Use

Publications (1)

Publication Number Publication Date
ATE427750T1 true ATE427750T1 (de) 2009-04-15

Family

ID=9935900

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03725356T ATE427750T1 (de) 2002-05-01 2003-05-01 Verwendung von xenon zur kontrolle von neurologischen defiziten im zusammenhang mit kardiopulmonalem bypass

Country Status (12)

Country Link
US (1) US7442383B2 (de)
EP (1) EP1499329B2 (de)
JP (2) JP4939751B2 (de)
AT (1) ATE427750T1 (de)
AU (1) AU2003227896B2 (de)
BR (1) BR0309624A (de)
CA (1) CA2483097C (de)
DE (1) DE60327068D1 (de)
ES (1) ES2323582T5 (de)
GB (1) GB0209998D0 (de)
MX (1) MXPA04010855A (de)
WO (1) WO2003092707A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0209998D0 (en) * 2002-05-01 2002-06-12 Protexeon Ltd Use
WO2005039600A2 (en) * 2003-10-21 2005-05-06 Aga Ab Use of xenon for the prevention of programmed cell death
GB0418540D0 (en) 2004-08-19 2004-09-22 Protexeon Ltd Use
EP1980261A1 (de) 2007-04-10 2008-10-15 Nicholas Peter Franks Verwendung von Helium mit Sauerstoff zur Bereitstellung von Neuroprotektion
EP1980260A1 (de) 2007-04-10 2008-10-15 Nicholas Peter Franks Verwendung hyperbarischer Bedingungen zur Bereitstellung von Neuroprotektion
CN110464709A (zh) 2012-08-10 2019-11-19 德克萨斯州大学系统董事会 用于治疗中风的神经保护性脂质体组合物和方法
EP4082552A1 (de) * 2013-03-15 2022-11-02 The Board of Regents of the University of Texas System Edelgasreiche flüssigkeiten sowie verfahren zu deren herstellung und verwendung
FR3021220B1 (fr) * 2014-05-21 2017-08-25 Air Liquide Association de xenon et d’un antioxydant pour lutter contre une maladie neurodegenerative de type maladie de parkinson
CA2968722C (en) * 2016-06-03 2022-06-07 Lakehead University In vivo detection of a xenon-binding cage molecule
EP3946508A4 (de) * 2019-03-25 2022-12-21 Mallinckrodt Pharmaceuticals Ireland Limited Gasfreisetzungssystem

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19709704C2 (de) * 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
US6589621B1 (en) * 1998-07-01 2003-07-08 Dow Global Technologies Inc. Thermally stable polyetheramines
DE19910986C2 (de) * 1999-03-11 2001-06-07 Aga Ab Verwendung von Xenon bei der Behandlung von Neurointoxikationen
GB9913677D0 (en) * 1999-06-11 1999-08-11 Imperial College Formulation
DE19933704A1 (de) * 1999-07-19 2001-01-25 Michael Georgieff Verwendung einer lipophile Gase enthaltenden Präparation zur Neuroprotektion und Neuroregeneration
GB9917822D0 (en) * 1999-07-29 1999-09-29 Imperial College Nmda antagonist
GB0209998D0 (en) * 2002-05-01 2002-06-12 Protexeon Ltd Use

Also Published As

Publication number Publication date
DE60327068D1 (de) 2009-05-20
AU2003227896B2 (en) 2008-08-14
EP1499329A1 (de) 2005-01-26
US7442383B2 (en) 2008-10-28
EP1499329B1 (de) 2009-04-08
GB0209998D0 (en) 2002-06-12
JP2005530750A (ja) 2005-10-13
ES2323582T3 (es) 2009-07-21
EP1499329B2 (de) 2012-05-23
ES2323582T5 (es) 2012-08-22
BR0309624A (pt) 2005-02-09
JP2011102290A (ja) 2011-05-26
US20050238726A1 (en) 2005-10-27
JP4939751B2 (ja) 2012-05-30
WO2003092707A1 (en) 2003-11-13
MXPA04010855A (es) 2005-02-14
CA2483097C (en) 2011-07-12
AU2003227896A1 (en) 2003-11-17
CA2483097A1 (en) 2003-11-13

Similar Documents

Publication Publication Date Title
DK1615952T3 (da) Fremgangsmåder til behandling af betændelsestilstande med specifikke, til humant angiopoietin-2-bindende midler
ATE495739T1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
TW200606177A (en) Glycoprotein VI antibodies and methods thereof
NO20054371L (no) Somatostatin-dopamin kimaere analoger
ATE427750T1 (de) Verwendung von xenon zur kontrolle von neurologischen defiziten im zusammenhang mit kardiopulmonalem bypass
DE60328517D1 (de) Neue verwendung von lycopin zur behandlung von erkrankungen im zusammenhang mit androgenwirkung
ATE406351T1 (de) Kondensierte heteroyralderivate zur verwendung als p38-kinase-inhibitoren
DE602004021585D1 (de) 5,7-DIAMINOPYRAZOLOi4,3-D PYRIMIDINE ZUR VERWENDUNG IN DER BEHANDLUNG VON BLUTHOCHDRUCK
TW200603830A (en) Methods for treating bone cancer pain by administering a nerve growth factor antagonist
DE602005026866D1 (de) Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
RS20150135A1 (en) TREATMENT WITH ANTI-VEGF ANTIBODIES
ATE319465T1 (de) Therapeutische verwendung von extrakten aus sophora flavescens oder sophora subprostrata
DE60130797D1 (de) Verwendung von spezifischen erbb4 antagonisten zur behandlung von stenose
EA201070730A1 (ru) Гуманизированные антитела, специфичные к фактору фон виллебранда
ATE445402T1 (de) Neue verwendung von pde5-hemmern
DE602005013788D1 (de) ckrox-Peptide und ihre Analoge zur Behandlung von Hautalterung
EP1660682A4 (de) Antisense-modulation von p38-mitogen-aktivierter proteinkinase-expression
NO20055563L (no) Midler for behandlingen av lavere abdominale lidelser
WO2004004653A3 (en) Methods for treating psychosis associated with interferon-alpha therapy
ATE525073T1 (de) Verwendung von pyrimidylaminobenzamiden zur behandlung von durch modulation einer tie-2 kinase-aktivität verursachten krankheiten
DE60328603D1 (de) Prodrugs von imidazol-derivaten, zur verwendung als protonenpumpen-hemmer zur behandlung von z.b. peptischen magengeschwüren
ATE447426T1 (de) Elektromagnetische stimulation bei patienten mit osteoporose
ATE380554T1 (de) Verwendung von xenon mit hypothermie zur behandlung von neugeborenen-asphyxie
DE60219940D1 (de) Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie
DE60221352D1 (de) Zusammensetzung und kit zur verwendung in der tumorbehandlung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties